PT  - JOURNAL ARTICLE
AU  - ULRICH H. WEIDLE
AU  - FABIAN BIRZELE
AU  - GEORG TIEFENTHALER
TI  - Potential of Protein-based Anti-metastatic Therapy with Serpins and Inter α-Trypsin Inhibitors
AID  - 10.21873/cgp.20081
DP  - 2018 Jul 01
TA  - Cancer Genomics - Proteomics
PG  - 225--238
VI  - 15
IP  - 4
4099  - http://cgp.iiarjournals.org/content/15/4/225.short
4100  - http://cgp.iiarjournals.org/content/15/4/225.full
SO  - Cancer Genomics Proteomics2018 Jul 01; 15
AB  - In this review we summarize the principles of anti-metastatic therapy with selected serpin family proteins, such as pigment epithelial-derived factor (PEDF) and maspin, as well as inter α-trypsin inhibitor (IαIs) light chains (bikunin) and heavy chains (ITIHs). Case-by-case, antimetastatic activity may be dependent or independent of the protease-inhibitory activity of the corresponding proteins. We discuss the incidence of target deregulation in different tumor entities, mechanisms of deregulation, context-dependent functional issues as well as in vitro and in vivo target validation studies with transfected tumor cells or recombinant protein as anti-metastatic agents. Finally, we comment on possible clinical evaluation of these proteins in adjuvant therapy.